Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Cediranib when added to chemotherapy is more
effective than chemotherapy alone in prolonging life expectancy and slowing disease
progression in patients with previously untreated metastatic colorectal cancer.